loading
Schlusskurs vom Vortag:
$19.90
Offen:
$19.95
24-Stunden-Volumen:
692.41K
Relative Volume:
0.30
Marktkapitalisierung:
$2.47B
Einnahmen:
$715.22M
Nettoeinkommen (Verlust:
$-250.10M
KGV:
-9.6771
EPS:
-2.03
Netto-Cashflow:
$-205.58M
1W Leistung:
-2.05%
1M Leistung:
+5.48%
6M Leistung:
-34.57%
1J Leistung:
-47.50%
1-Tages-Spanne:
Value
$19.16
$20.32
1-Wochen-Bereich:
Value
$19.09
$20.44
52-Wochen-Spanne:
Value
$16.10
$41.94

Apellis Pharmaceuticals Inc Stock (APLS) Company Profile

Name
Firmenname
Apellis Pharmaceuticals Inc
Name
Telefon
617-977-5700
Name
Adresse
100 FIFTH AVENUE, WALTHAM, KY
Name
Mitarbeiter
710
Name
Twitter
@ApellisPharma
Name
Nächster Verdiensttermin
2024-12-05
Name
Neueste SEC-Einreichungen
Name
APLS's Discussions on Twitter

Vergleichen Sie APLS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
APLS
Apellis Pharmaceuticals Inc
19.65 2.50B 715.22M -250.10M -205.58M -2.03
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.84 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
570.82 60.56B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
331.50 42.41B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
588.61 34.96B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.96 31.99B 3.81B -644.79M -669.77M -6.24

Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-05-09 Herabstufung BofA Securities Buy → Neutral
2025-05-09 Herabstufung Raymond James Strong Buy → Outperform
2025-04-29 Eingeleitet Cantor Fitzgerald Overweight
2024-12-17 Herabstufung Goldman Buy → Neutral
2024-11-21 Eingeleitet Morgan Stanley Equal-Weight
2024-10-25 Eingeleitet RBC Capital Mkts Sector Perform
2024-10-16 Eingeleitet Scotiabank Sector Outperform
2024-10-16 Eingeleitet William Blair Outperform
2024-05-31 Eingeleitet Piper Sandler Neutral
2024-02-05 Hochstufung Jefferies Hold → Buy
2023-12-14 Herabstufung Wells Fargo Overweight → Equal Weight
2023-11-09 Eingeleitet Goldman Buy
2023-11-02 Eingeleitet Mizuho Neutral
2023-10-06 Hochstufung JP Morgan Neutral → Overweight
2023-09-15 Hochstufung Wells Fargo Equal Weight → Overweight
2023-08-29 Bestätigt Citigroup Buy
2023-08-03 Herabstufung JP Morgan Overweight → Neutral
2023-08-01 Herabstufung BofA Securities Buy → Neutral
2023-01-03 Herabstufung Wells Fargo Overweight → Equal Weight
2022-11-10 Herabstufung Jefferies Buy → Hold
2022-07-19 Eingeleitet H.C. Wainwright Buy
2022-06-17 Fortgesetzt Stifel Buy
2022-04-14 Herabstufung ROTH Capital Neutral → Sell
2021-12-08 Eingeleitet Wells Fargo Overweight
2021-11-29 Herabstufung ROTH Capital Buy → Neutral
2021-09-10 Bestätigt BMO Capital Markets Outperform
2021-09-10 Bestätigt Credit Suisse Neutral
2021-09-10 Bestätigt Needham Buy
2021-09-10 Bestätigt Oppenheimer Outperform
2021-09-10 Herabstufung Wedbush Outperform → Neutral
2021-08-19 Eingeleitet Jefferies Buy
2021-08-19 Hochstufung Wedbush Neutral → Outperform
2021-05-21 Eingeleitet UBS Buy
2021-04-16 Eingeleitet Goldman Buy
2020-11-19 Eingeleitet Needham Buy
2020-09-01 Eingeleitet Stifel Buy
2020-07-20 Eingeleitet ROTH Capital Buy
2020-06-17 Eingeleitet BTIG Research Neutral
2020-04-01 Eingeleitet Raymond James Strong Buy
2020-03-31 Eingeleitet BMO Capital Markets Outperform
2020-03-11 Hochstufung Wedbush Underperform → Neutral
2020-01-07 Eingeleitet SVB Leerink Mkt Perform
2019-12-19 Eingeleitet BofA/Merrill Buy
2019-11-22 Eingeleitet Wedbush Underperform
2019-11-05 Eingeleitet Credit Suisse Neutral
2019-08-01 Bestätigt Cantor Fitzgerald Overweight
2019-07-12 Hochstufung JP Morgan Neutral → Overweight
2019-03-29 Eingeleitet Robert W. Baird Outperform
2019-01-23 Herabstufung JP Morgan Overweight → Neutral
2018-07-30 Hochstufung B. Riley FBR Neutral → Buy
2018-05-24 Eingeleitet Cantor Fitzgerald Overweight
2018-04-12 Herabstufung B. Riley FBR, Inc. Buy → Neutral
2018-02-08 Eingeleitet B. Riley FBR, Inc. Buy
Alle ansehen

Apellis Pharmaceuticals Inc Aktie (APLS) Neueste Nachrichten

pulisher
07:51 AM

Apellis Pharmaceuticals to Host Conference Call on July 31, 2025 - GuruFocus

07:51 AM
pulisher
07:26 AM

Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results - The Manila Times

07:26 AM
pulisher
Jul 23, 2025

Is Apellis Pharmaceuticals Inc. a good long term investmentDynamic investment growth - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

What analysts say about Apellis Pharmaceuticals Inc. stockFree Popular Stock Recommendations - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

Complement 3 Glomerulopathy Market Expected to Experience Major Growth by 2034, According to DelveInsight | NovelMed Therapeutics, Apellis Pharma, Novartis, Amyndas Pharma - Barchart.com

Jul 23, 2025
pulisher
Jul 23, 2025

Apellis Pharmaceuticals Inc. Stock Analysis and ForecastOutstanding trading profits - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

What drives Apellis Pharmaceuticals Inc. stock priceExceptional market performance - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

Intermediate Age-Related Macular Degeneration Market Research 2025-2035 Featuring Novartis, Allegro Ophthalmics, and Apellis PharmaceuticalsResearchAndMarkets.com - FinancialContent

Jul 21, 2025
pulisher
Jul 18, 2025

Apellis Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (15 Ratings) - Benzinga

Jul 18, 2025
pulisher
Jul 18, 2025

Fierce Biotech Layoff Tracker 2025: Sail shrinks crew again; Sarepta lays off 500 staffers - Fierce Biotech

Jul 18, 2025
pulisher
Jul 16, 2025

APLS Stock Update: B of A Securities Raises Price Target | APLS - GuruFocus

Jul 16, 2025
pulisher
Jul 15, 2025

Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting - The Manila Times

Jul 15, 2025
pulisher
Jul 15, 2025

Apellis Reveals 48-Month SYFOVRE Data: 5 Key Studies Show Promise for Geographic Atrophy Treatment - Stock Titan

Jul 15, 2025
pulisher
Jul 14, 2025

H.C. Wainwright reiterates Buy rating on Apellis Pharmaceuticals stock By Investing.com - Investing.com Canada

Jul 14, 2025
pulisher
Jul 14, 2025

How the (APLS) price action is used to our Advantage - news.stocktradersdaily.com

Jul 14, 2025
pulisher
Jul 11, 2025

Apellis Pharmaceuticals (APLS) Receives a Buy from Cantor Fitzgerald - The Globe and Mail

Jul 11, 2025
pulisher
Jul 11, 2025

Apellis stock holds Outperform rating at William Blair amid Izervay competition - Investing.com Canada

Jul 11, 2025
pulisher
Jul 10, 2025

Apellis Sells Aspaveli Ex-US Royalties to Sobi for Up to $300M - MSN

Jul 10, 2025
pulisher
Jul 10, 2025

Cantor Fitzgerald reiterates Apellis stock Overweight rating with $39 target By Investing.com - Investing.com Canada

Jul 10, 2025
pulisher
Jul 10, 2025

Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS) and Charles River Labs (CRL) - The Globe and Mail

Jul 10, 2025
pulisher
Jul 08, 2025

16 Most Promising Stocks According to Wall Street Analysts - Insider Monkey

Jul 08, 2025
pulisher
Jul 06, 2025

Morgan Stanley Raises PT on Apellis Pharmaceuticals (APLS) to $26, Keeps a Hold Rating - Insider Monkey

Jul 06, 2025
pulisher
Jul 06, 2025

Apellis stock surges after Sobi $300 million royalty deal - MSN

Jul 06, 2025
pulisher
Jul 06, 2025

Morgan Stanley raised the Target Price of Apellis Pharmaceuticals (APLS.US) to $26 and maintained a "Hold" rating. - 富途牛牛

Jul 06, 2025
pulisher
Jul 05, 2025

Apellis Pharmaceuticals, Inc. (APLS) Insider Activity Signals Possible Market Mispricing - MSN

Jul 05, 2025
pulisher
Jul 03, 2025

SHAREHOLDER ALERT: Potential Recovery for Apellis Pharmaceuticals, Inc. (APLS) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire

Jul 03, 2025
pulisher
Jul 03, 2025

WilmerHale Advises Apellis Pharmaceuticals in Purchase Agreement with Sobi - WilmerHale

Jul 03, 2025
pulisher
Jul 03, 2025

(APLS) Trading Advice - news.stocktradersdaily.com

Jul 03, 2025
pulisher
Jul 03, 2025

Apellis signs royalty purchase deal with Sobi for Aspaveli - MSN

Jul 03, 2025
pulisher
Jul 03, 2025

Apellis Stock Rises on $300M Royalty Deal With Sobi for Aspaveli - MSN

Jul 03, 2025
pulisher
Jul 03, 2025

Analysts Offer Insights on Healthcare Companies: BeiGene (ONC), Apellis Pharmaceuticals (APLS) and Pliant Therapeutics (PLRX) - The Globe and Mail

Jul 03, 2025
pulisher
Jul 02, 2025

What 13 Analyst Ratings Have To Say About Apellis Pharmaceuticals - Nasdaq

Jul 02, 2025
pulisher
Jul 02, 2025

Mizuho maintains Neutral rating on Apellis stock amid royalty deal with Sobi - Investing.com Canada

Jul 02, 2025
pulisher
Jul 01, 2025

Apellis to receive $300 million in royalty deal with Sobi By Investing.com - Investing.com South Africa

Jul 01, 2025
pulisher
Jul 01, 2025

Apellis to receive $300 million in royalty deal with Sobi - Investing.com India

Jul 01, 2025

Finanzdaten der Apellis Pharmaceuticals Inc-Aktie (APLS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Apellis Pharmaceuticals Inc-Aktie (APLS) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Francois Cedric
Chief Executive Officer
Jul 17 '25
Sale
20.21
19,725
398,735
331,605
Watson David O.
General Counsel
Jul 16 '25
Sale
19.55
5,000
97,750
128,730
$23.62
price up icon 3.28%
$36.59
price up icon 1.62%
$103.43
price up icon 0.09%
$27.66
price down icon 1.21%
$113.95
price down icon 0.57%
biotechnology ONC
$296.05
price up icon 0.44%
Kapitalisierung:     |  Volumen (24h):